{"protocolSection":{"identificationModule":{"nctId":"NCT04475549","orgStudyIdInfo":{"id":"C6463-201"},"secondaryIdInfos":[{"id":"CY6463","type":"OTHER","domain":"Cyclerion Therapeutics"}],"organization":{"fullName":"Tisento Therapeutics","class":"INDUSTRY"},"briefTitle":"Phase 2a Study of IW-6463 in Adults Diagnosed With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)","officialTitle":"A Phase 2a Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Individuals With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)"},"statusModule":{"statusVerifiedDate":"2023-11","overallStatus":"TERMINATED","whyStopped":"Study terminated due to enrollment challenges.","startDateStruct":{"date":"2020-11-13","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-01-23","type":"ACTUAL"},"completionDateStruct":{"date":"2022-01-23","type":"ACTUAL"},"studyFirstSubmitDate":"2020-07-14","studyFirstSubmitQcDate":"2020-07-14","studyFirstPostDateStruct":{"date":"2020-07-17","type":"ACTUAL"},"resultsFirstSubmitDate":"2023-10-17","resultsFirstSubmitQcDate":"2023-11-13","resultsFirstPostDateStruct":{"date":"2023-11-15","type":"ACTUAL"},"dispFirstSubmitDate":"2023-01-20","dispFirstSubmitQcDate":"2023-11-13","dispFirstPostDateStruct":{"date":"2023-11-15","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-11-13","lastUpdatePostDateStruct":{"date":"2023-11-15","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Tisento Therapeutics","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a single-arm study to evaluate safety and tolerability of oral IW-6463 in adults diagnosed with MELAS.","detailedDescription":"IW-6463 tablets will be orally administered once-daily (QD) for up to 29 days"},"conditionsModule":{"conditions":["MELAS"],"keywords":["mitochondrial disease"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","interventionModelDescription":"Open-label, single-arm study with daily dosing for up to 29 days.","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":8,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"IW-6463","type":"EXPERIMENTAL","description":"Open-label IW-6463 15 mg once daily (QD), with possibility to dose reduce to 10 mg.","interventionNames":["Drug: IW-6463 Tablets"]}],"interventions":[{"type":"DRUG","name":"IW-6463 Tablets","description":"IW-6463 tablets administered orally (daily)","armGroupLabels":["IW-6463"],"otherNames":["CY6463"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Study Drug Dose Reductions or Discontinuations Due to ≥ 1 Treatment Emergent Adverse Event (TEAE)","description":"A TEAE is defined as an adverse event (AE) with an onset that occurs between the first dose of study drug and the end of study period. AEs are defined as an untoward medical occurrence that does not necessarily have a causal relationship with study drug treatment.","timeFrame":"From first dose date to Day 43 (±4)"},{"measure":"Number of Participants Who Experienced ≥1 AE, TEAE, Serious AE (SAE), or TEAE of Special Interest (AESI)","description":"AEs are defined as an untoward medical occurrence that does not necessarily have a causal relationship with study drug treatment. A TEAE is defined as an AE with an onset that occurs from the first dose of study drug up until the end of study period. An SAE is an AE that fulfills 1 or more of the following: results in death; is immediately life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; results in a congenital abnormality or birth defect; is an important medical event that may jeopardize the participant or may require medical intervention to prevent 1 of the outcomes listed above. Events were categorized as mild, moderate, or severe and as related or unrelated to study drug. AESIs include bleeding events, symptomatic hypotensive events and/or tachycardia, dizziness, syncope, and TEAEs related to change of neurobehaviors (ie, suicidality or euphoria).","timeFrame":"From first dose date to Day 43 (±4)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Prior genetic confirmation of a known mitochondrial disease mutation\n2. Neurological features of MELAS (can be based on medical history)\n3. Elevated plasma lactate levels at Screening Visit (≥1.0 mmol/L)\n4. Women of childbearing potential must have a negative pregnancy test prior to randomization and must agree to use protocol-specified contraception from the Screening Visit through 90 days after the final dose of study drug.\n5. Male participants must be surgically sterile by vasectomy (conducted ≥60 days before the Screening Visit or confirmed via sperm analysis) or must agree to use protocol-specified contraception and agree to refrain from sperm donation from the Screening Visit through 90 days after the final dose of study drug.\n6. Other inclusion criteria per protocol\n\nExclusion Criteria:\n\n1. Positive pregnancy test at Screening or on Day 1\n2. Hypotension defined as systolic blood pressure (BP) ≤90 mmHg or diastolic BP ≤60 mmHg at Screening or predose at Day 1\n3. Hypertension defined as systolic BP \\>160 mmHg or diastolic BP \\>100 mmHg, at Screening or predose at Day 1\n4. Uncontrolled diabetes\n5. Severe gastrointestinal dysmotility as determined by the investigator that may impact compliance and/or oral drug administration, absorption and exposure.\n6. Unable to fast for 3-4 hours after a meal\n7. Unable or unwilling to adhere to the study schedule, lifestyle restrictions, assessment requirements or, in the clinical judgment of the investigator, is otherwise not suitable for study participation.\n8. Current or past history of clinically significant cardiomyopathy and/or cardiac conduction abnormality\n9. Used any nicotine-containing products (eg, cigarettes, e-cigarettes, vape pens, cigars) within 1 month of enrollment\n10. Other exclusion criteria per protocol","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Chad Glasser, PharmD","affiliation":"Cyclerion Therapeutics, Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Children's National Hospital of DC","city":"Washington","state":"District of Columbia","zip":"20010","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}},{"facility":"Johns Hopkins University","city":"Baltimore","state":"Maryland","zip":"21205","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Massachusetts General Hospital","city":"Boston","state":"Massachusetts","zip":"02114","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Columbia University","city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Children's Hospital of Philadelphia","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95233,"lon":-75.16379}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"IW-6463","description":"Open-label IW-6463 15 mg once daily (QD), with possibility to dose reduce to 10 mg."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"8"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"8"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"IW-6463","description":"Open-label IW-6463 15 mg QD, with possibility to dose reduce to 10 mg."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"8"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"32.8","spread":"12.41"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"5"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"3"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"8"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"6"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Study Drug Dose Reductions or Discontinuations Due to ≥ 1 Treatment Emergent Adverse Event (TEAE)","description":"A TEAE is defined as an adverse event (AE) with an onset that occurs between the first dose of study drug and the end of study period. AEs are defined as an untoward medical occurrence that does not necessarily have a causal relationship with study drug treatment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"From first dose date to Day 43 (±4)","groups":[{"id":"OG000","title":"IW-6463","description":"Open-label IW-6463 15 mg QD, with possibility to dose reduce to 10 mg."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"classes":[{"title":"Dose reduction due to TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Study drug discontinuation due to TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Experienced ≥1 AE, TEAE, Serious AE (SAE), or TEAE of Special Interest (AESI)","description":"AEs are defined as an untoward medical occurrence that does not necessarily have a causal relationship with study drug treatment. A TEAE is defined as an AE with an onset that occurs from the first dose of study drug up until the end of study period. An SAE is an AE that fulfills 1 or more of the following: results in death; is immediately life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; results in a congenital abnormality or birth defect; is an important medical event that may jeopardize the participant or may require medical intervention to prevent 1 of the outcomes listed above. Events were categorized as mild, moderate, or severe and as related or unrelated to study drug. AESIs include bleeding events, symptomatic hypotensive events and/or tachycardia, dizziness, syncope, and TEAEs related to change of neurobehaviors (ie, suicidality or euphoria).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose date to Day 43 (±4)","groups":[{"id":"OG000","title":"IW-6463","description":"Open-label IW-6463 15 mg QD, with possibility to dose reduce to 10 mg."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"classes":[{"title":"Any AE","categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]},{"title":"Any pretreatment AE","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Any TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]},{"title":"Any severe TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Any study drug-related TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]},{"title":"Any SAE","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Any TEAE leading to study drug discontinuation","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Any TEAE leading to death","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Any treatment-emergent AESI","categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"From signing of informed consent (all-cause mortality) or first dose date (adverse events) to Day 43 (±4).","eventGroups":[{"id":"EG000","title":"IW-6463","description":"Open-label IW-6463 15 mg QD, with possibility to dose reduce to 10 mg.","deathsNumAffected":0,"deathsNumAtRisk":8,"seriousNumAffected":0,"seriousNumAtRisk":8,"otherNumAffected":8,"otherNumAtRisk":8}],"otherEvents":[{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Verbatim term: \"metabolic stroke-like event\"","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Disturbance in attention","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Dysarthria","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":8}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Frequent bowel movements","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Feeling abnormal","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Impaired healing","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":8}]},{"term":"Blindness transient","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Crystal urine present","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Oxygen saturation decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Sleep disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Postural orthostatic tachycardia syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Eye naevus","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Nail growth abnormal","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]},{"term":"Onychoclasis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"PI may publish or disclose the results of the study 24 months after final data lock provided that sponsor can review the publication prior to public release, sponsor can request removal of confidential information of sponsor (not including results of trial), and sponsor can request a publication delay in order to protect potentially patentable information. Furthermore, if a publication committee is developing an initial publication, PI is to delay disclosure until that publication is published."},"pointOfContact":{"title":"Cyclerion Clinical Development","organization":"Cyclerion Therapeutics, Inc.","email":"info@cyclerion.com","phone":"1-857-327-8778"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2021-07-23","uploadDate":"2023-01-26T21:39","filename":"Prot_000.pdf","size":1421087},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2022-03-21","uploadDate":"2023-01-26T21:40","filename":"SAP_001.pdf","size":1415329}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2023-11-09","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D000017241","term":"MELAS Syndrome"},{"id":"D000017237","term":"Mitochondrial Encephalomyopathies"},{"id":"D000000138","term":"Acidosis"},{"id":"D000000140","term":"Acidosis, Lactic"}],"ancestors":[{"id":"D000000137","term":"Acid-Base Imbalance"},{"id":"D000008659","term":"Metabolic Diseases"},{"id":"D000017240","term":"Mitochondrial Myopathies"},{"id":"D000009135","term":"Muscular Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000020739","term":"Brain Diseases, Metabolic, Inborn"},{"id":"D000001928","term":"Brain Diseases, Metabolic"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000059345","term":"Cerebral Small Vessel Diseases"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000009468","term":"Neuromuscular Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000008661","term":"Metabolism, Inborn Errors"},{"id":"D000030342","term":"Genetic Diseases, Inborn"},{"id":"D000028361","term":"Mitochondrial Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M3189","name":"Acidosis","asFound":"Acidosis","relevance":"HIGH"},{"id":"M23031","name":"Mitochondrial Diseases","relevance":"LOW"},{"id":"M19225","name":"Mitochondrial Encephalomyopathies","asFound":"Mitochondrial Encephalomyopathies","relevance":"HIGH"},{"id":"M3190","name":"Acidosis, Lactic","asFound":"Lactic Acidosis","relevance":"HIGH"},{"id":"M16045","name":"Syndrome","relevance":"LOW"},{"id":"M19229","name":"MELAS Syndrome","asFound":"Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes","relevance":"HIGH"},{"id":"M3188","name":"Acid-Base Imbalance","relevance":"LOW"},{"id":"M11329","name":"Metabolic Diseases","relevance":"LOW"},{"id":"M11782","name":"Muscular Diseases","relevance":"LOW"},{"id":"M19228","name":"Mitochondrial Myopathies","relevance":"LOW"},{"id":"M11787","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M4895","name":"Brain Diseases, Metabolic","relevance":"LOW"},{"id":"M22188","name":"Brain Diseases, Metabolic, Inborn","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M29127","name":"Cerebral Small Vessel Diseases","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M12101","name":"Neuromuscular Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M11331","name":"Metabolism, Inborn Errors","relevance":"LOW"},{"id":"M23376","name":"Genetic Diseases, Inborn","relevance":"LOW"},{"id":"T3840","name":"Mitochondrial Encephalomyopathy Lactic Acidosis and Stroke-like Episodes","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC18","name":"Nutritional and Metabolic Diseases"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"BC16","name":"Diseases and Abnormalities at or Before Birth"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":true}